http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+11/26659851.html si-local-file:///var/storage/secattach/20260617/26659851.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+11/26659851.html Wed, 17 Jun 2026 16:06:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+11/26659851.html si-local-file:///var/storage/secattach/20260617/26659851.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+11/26659851.html Wed, 17 Jun 2026 16:06:00 -0400 O.00187291 RIGL http://www.streetinsider.com/Corporate+News/Rigel+Pharmaceuticals+closes+%2470M+VEPPANU+license+deal+with+ARVINAS+and+PFIZER/26653928.html <p>Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced the closing of its exclusive global license agreement with Arvinas, Inc. and Pfizer Inc. for VEPPANU (vepdegestrant), a breast cancer treatment approved by the U.S. Food and Drug Administration.</p><p>The agreement, effective June 11, 2026, required Rigel to make an upfront payment of $70.0 million, split evenly between Arvinas and Pfizer. The deal closed following early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions.</p><p>VEPPANU is FDA-approved for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized http://www.streetinsider.com/Corporate+News/Rigel+Pharmaceuticals+closes+%2470M+VEPPANU+license+deal+with+ARVINAS+and+PFIZER/26653928.html Tue, 16 Jun 2026 16:02:04 -0400 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANU^TM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713069-1&amp;h=2686386897&amp;u=https%3A%2F%2Fwww.rigel.com%2Finvestors%2Fnews-events%2Fpress-releases%2Fdetail%2F437%2Frigel-enters-exclusive-global-licensing-agreement-for&amp;a=announced" target="_blank" rel="nofollow">announced</a> it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer) to develop, manufacture and commercialize VEPPANU. VEPPANU is approved by http://www.streetinsider.com/Press+Releases/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANU^TM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713069-1&amp;h=2686386897&amp;u=https%3A%2F%2Fwww.rigel.com%2Finvestors%2Fnews-events%2Fpress-releases%2Fdetail%2F437%2Frigel-enters-exclusive-global-licensing-agreement-for&amp;a=announced" target="_blank" rel="nofollow">announced</a> it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer) to develop, manufacture and commercialize VEPPANU. VEPPANU is approved by http://www.streetinsider.com/Press+Releases/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANU^TM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713069-1&amp;h=2686386897&amp;u=https%3A%2F%2Fwww.rigel.com%2Finvestors%2Fnews-events%2Fpress-releases%2Fdetail%2F437%2Frigel-enters-exclusive-global-licensing-agreement-for&amp;a=announced" target="_blank" rel="nofollow">announced</a> it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer) to develop, manufacture and commercialize VEPPANU. VEPPANU is approved by http://www.streetinsider.com/Press+Releases/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANU^TM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713069-1&amp;h=2686386897&amp;u=https%3A%2F%2Fwww.rigel.com%2Finvestors%2Fnews-events%2Fpress-releases%2Fdetail%2F437%2Frigel-enters-exclusive-global-licensing-agreement-for&amp;a=announced" target="_blank" rel="nofollow">announced</a> it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer) to develop, manufacture and commercialize VEPPANU. VEPPANU is approved by http://www.streetinsider.com/Press+Releases/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANU^TM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713069-1&amp;h=2686386897&amp;u=https%3A%2F%2Fwww.rigel.com%2Finvestors%2Fnews-events%2Fpress-releases%2Fdetail%2F437%2Frigel-enters-exclusive-global-licensing-agreement-for&amp;a=announced" target="_blank" rel="nofollow">announced</a> it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer) to develop, manufacture and commercialize VEPPANU. VEPPANU is approved by http://www.streetinsider.com/PRNewswire/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANU^TM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713069-1&amp;h=2686386897&amp;u=https%3A%2F%2Fwww.rigel.com%2Finvestors%2Fnews-events%2Fpress-releases%2Fdetail%2F437%2Frigel-enters-exclusive-global-licensing-agreement-for&amp;a=announced" target="_blank" rel="nofollow">announced</a> it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer) to develop, manufacture and commercialize VEPPANU. VEPPANU is approved by http://www.streetinsider.com/PRNewswire/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANU^TM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713069-1&amp;h=2686386897&amp;u=https%3A%2F%2Fwww.rigel.com%2Finvestors%2Fnews-events%2Fpress-releases%2Fdetail%2F437%2Frigel-enters-exclusive-global-licensing-agreement-for&amp;a=announced" target="_blank" rel="nofollow">announced</a> it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer) to develop, manufacture and commercialize VEPPANU. VEPPANU is approved by http://www.streetinsider.com/PRNewswire/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANU^TM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4713069-1&amp;h=2686386897&amp;u=https%3A%2F%2Fwww.rigel.com%2Finvestors%2Fnews-events%2Fpress-releases%2Fdetail%2F437%2Frigel-enters-exclusive-global-licensing-agreement-for&amp;a=announced" target="_blank" rel="nofollow">announced</a> it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer) to develop, manufacture and commercialize VEPPANU. VEPPANU is approved by http://www.streetinsider.com/PRNewswire/Rigel+Announces+Closing+of+Licensing+Agreement+for+VEPPANU%E2%84%A2+%28vepdegestrant%29/26653909.html Tue, 16 Jun 2026 16:01:00 -0400 A.06822034 O.00187291 O.20026344 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Schorno+Dean+L/26600668.html si-local-file:///var/storage/secattach/20260603/26600668.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Schorno+Dean+L/26600668.html Wed, 03 Jun 2026 18:04:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Schorno+Dean+L/26600668.html si-local-file:///var/storage/secattach/20260603/26600668.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Schorno+Dean+L/26600668.html Wed, 03 Jun 2026 18:04:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Santos+David+A/26600661.html si-local-file:///var/storage/secattach/20260603/26600661.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Santos+David+A/26600661.html Wed, 03 Jun 2026 18:03:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Santos+David+A/26600661.html si-local-file:///var/storage/secattach/20260603/26600661.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Santos+David+A/26600661.html Wed, 03 Jun 2026 18:03:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+RODRIGUEZ+RAUL+R/26600658.html si-local-file:///var/storage/secattach/20260603/26600658.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+RODRIGUEZ+RAUL+R/26600658.html Wed, 03 Jun 2026 18:02:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+RODRIGUEZ+RAUL+R/26600658.html si-local-file:///var/storage/secattach/20260603/26600658.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+RODRIGUEZ+RAUL+R/26600658.html Wed, 03 Jun 2026 18:02:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Rojkjaer+Lisa/26600659.html si-local-file:///var/storage/secattach/20260603/26600659.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Rojkjaer+Lisa/26600659.html Wed, 03 Jun 2026 18:02:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Rojkjaer+Lisa/26600659.html si-local-file:///var/storage/secattach/20260603/26600659.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Rojkjaer+Lisa/26600659.html Wed, 03 Jun 2026 18:02:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Furey+Raymond+J./26600654.html si-local-file:///var/storage/secattach/20260603/26600654.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Furey+Raymond+J./26600654.html Wed, 03 Jun 2026 18:01:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Furey+Raymond+J./26600654.html si-local-file:///var/storage/secattach/20260603/26600654.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+01++Filed+by%3A+Furey+Raymond+J./26600654.html Wed, 03 Jun 2026 18:01:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+May+26++Filed+by%3A+Ali-Jackson+Kamil/26567666.html si-local-file:///var/storage/secattach/20260528/26567666.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+May+26++Filed+by%3A+Ali-Jackson+Kamil/26567666.html Thu, 28 May 2026 16:19:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+May+26++Filed+by%3A+Ali-Jackson+Kamil/26567666.html si-local-file:///var/storage/secattach/20260528/26567666.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+May+26++Filed+by%3A+Ali-Jackson+Kamil/26567666.html Thu, 28 May 2026 16:19:00 -0400 O.00187291 RIGL http://www.streetinsider.com/Press+Releases/Rigel+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26553899.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that <person value="APIN:4124744503">Raul Rodriguez</person>, the company's president and CEO, will present a company overview at the <span>Jefferies Global Healthcare Conference</span> on <chron>Wednesday, June 3, 2026</chron>, at <chron>8:45 a.m. ET</chron> in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>.</p><p>To access the live webcast or archived recording, visit the Investor Relations section of the company's website at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4697059-1&amp;h=245908667&amp;u=http%3A%2F%2Fwww.rigel.com%2F&amp;a=www.rigel.com" target="_blank" rel="nofollow">www.rigel.com</a>. Please connect to Rigel's website prior http://www.streetinsider.com/Press+Releases/Rigel+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26553899.html Wed, 27 May 2026 08:05:00 -0400 O.00187291 RIGL http://www.streetinsider.com/Press+Releases/Rigel+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26553899.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>May 27, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that <person value="APIN:4124744503">Raul Rodriguez</person>, the company's president and CEO, will present a company overview at the <span>Jefferies Global Healthcare Conference</span> on <chron>Wednesday, June 3, 2026</chron>, at <chron>8:45 a.m. ET</chron> in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>.</p><p>To access the live webcast or archived recording, visit the Investor Relations section of the company's website at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4697059-1&amp;h=245908667&amp;u=http%3A%2F%2Fwww.rigel.com%2F&amp;a=www.rigel.com" target="_blank" rel="nofollow">www.rigel.com</a>. Please connect to Rigel's website prior http://www.streetinsider.com/Press+Releases/Rigel+to+Present+at+the+Jefferies+Global+Healthcare+Conference/26553899.html Wed, 27 May 2026 08:05:00 -0400 O.00187291 RIGL